| || |
|Page 1 of 1 || Previous | Next |
| | DIABETES IN CONTROL
DECEMBER 21, 2013 [CSII] ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #18: Insulin, Part 3 of 3
Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor Continuous Subcutaneous Insulin Infusion (CSII) PEDIATRICS David Maahs, MD, PhD, and H.
| || |
| || || || |
TOPIX [CSII] Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes.
| SATURDAY, AUGUST 15, 2015
Clinical trials have demonstrated that in individuals with type 1 diabetes the use of CSII
pump resulted in better glucose control To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. MORE >>
TOPIX [CSII] Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes
| SUNDAY, FEBRUARY 6, 2011
Diabetes Research and Clinical Practice Key: citeulike:8773143 Posts Export Citation Likes Abstract Clinical trials have demonstrated that in individuals with type 1 diabetes the use of CSII
pump resulted in better glucose control MORE >>
YOUR DIABETES MAY VARY [CSII] From the News Wire: FDA OKs Novolog for Kid's pumps
| TUESDAY, MARCH 18, 2008
Food and Drug Administration has approved NovoLog® (insulin aspart [rDNA origin] injection) for continuous subcutaneous insulin infusion (CSII
) by external insulin pump in pediatric patients between the ages of 4 and 18 years. Well it is news to me, that this is news. I just fugured people have been using it all along. FDA Approves NovoLog(R) for Use in Insulin Pumps by Children and Adolescents March 18, 2008 Novo Nordisk (NYSE: NVO) today announced that the U.S. MORE >>
YOUR DIABETES MAY VARY [CSII] Get you FDA Pre-Sub. Docket Comments here!
| THURSDAY, SEPTEMBER 20, 2012
The FDA currently has a docket open on “ Draft Guidance for Industry and Food and Drug Administration Staff; Medical Devices: The Pre-Submission Program and Meetings with FDA Staff; Availability.” link] So far there are just a few public comments. This docket is an opportunity to for the DOC to be seen by the FDA. It is a fairly dull issue and at first glance not specifically about T1D. However the FDA did bring pre-submission up in an email exchange about LGS. See this YDMV post. MORE >>